Kaijie Pan

Pfizer, Inc.

235 East 42 Street

New York, NY 10017

United States

SCHOLARLY PAPERS

5

DOWNLOADS
Rank 10,844

SSRN RANKINGS

Top 10,844

in Total Papers Downloads

8,279

SSRN CITATIONS
Rank 30,602

SSRN RANKINGS

Top 30,602

in Total Papers Citations

36

CROSSREF CITATIONS

0

Scholarly Papers (5)

1.

Six-Month Effectiveness of BNT162B2 mRNA COVID-19 Vaccine in a Large US Integrated Health System: A Retrospective Cohort Study

Number of pages: 40 Posted: 23 Aug 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente - Southern California Kaiser Permanente Medical Group, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 5,580 (2,855)

Abstract:

Loading...

2.

Nationwide Vaccination Campaign with BNT162b2 in Israel Demonstrates High Vaccine Effectiveness and Marked Declines in Incidence of SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths

Number of pages: 24 Posted: 24 Mar 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Pfizer, Inc., Ministry of Health (Israel) - Public Health Services, Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Ministry of Health (Israel) - Information Technology Department, Ministry of Health (Israel) - Information Technology Department, Pfizer Pharmaceuticals Israel Ltd, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 1,663 (20,504)
Citation 1

Abstract:

Loading...

COVID-19, SARS-CoV-2, vaccine effectiveness, prevention, mRNA vaccines, pandemic, observational study, epidemiology

3.

Infections, Hospitalizations, and Deaths Averted Via Direct Effects of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Vaccination Campaign, Israel

Number of pages: 25 Posted: 13 May 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Yale UniversityMinistry of Health (Israel) - Public Health Services, Harvard T.H. Chan School of Public Health - Center for Communicable Disease Dynamics, Ministry of Health (Israel) - Public Health Services, Pfizer Pharmaceuticals Israel Ltd, Ministry of Health (Israel) - Information Technology Department, Ministry of Health (Israel) - Information Technology Department, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 467 (115,822)
Citation 1

Abstract:

Loading...

COVID-19, SARS-CoV-2, cases averted, impact, hospitalizations, deaths, Israel, model, public health, pandemic

4.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 381 (146,551)
Citation 5

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

5.

Effectiveness of BNT162b2 mRNA COVID-19 Vaccine Against SARS-CoV-2 Variant Beta (B.1.351) Among Persons Identified Through Contact Tracing in Israel

Number of pages: 29 Posted: 13 Aug 2021
Ministry of Health (Israel) - Public Health Services, Pfizer, Inc., Harvard University - Center for Communicable Disease Dynamics, Pfizer, Inc., Ministry of Health (Israel), Israel Ministry of Health, Yale UniversityMinistry of Health (Israel) - Public Health Services, Sheba Medical Center - Central Virology Laboratory, Sheba Medical Center - Central Virology Laboratory, Sheba Medical Center - Central Virology Laboratory, Chaim Sheba Medical Center - Central Virology Laboratory, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc., Pfizer Pharmaceuticals Israel Ltd, Harvard T.H. Chan School of Public Health - Center for Communicable Disease Dynamics, Ministry of Health (Israel) - Public Health Services, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Ministry of Health (Israel) and Ministry of Health (Israel) - Department of Maternal and Child Health
Downloads 188 (297,578)
Citation 1

Abstract:

Loading...